Landfar Bio-medicine Balance Sheet Health
Financial Health criteria checks 6/6
Landfar Bio-medicine has a total shareholder equity of CN¥301.8M and total debt of CN¥28.4M, which brings its debt-to-equity ratio to 9.4%. Its total assets and total liabilities are CN¥611.3M and CN¥309.5M respectively.
Key information
9.4%
Debt to equity ratio
CN¥28.44m
Debt
Interest coverage ratio | n/a |
Cash | CN¥313.15m |
Equity | CN¥301.83m |
Total liabilities | CN¥309.48m |
Total assets | CN¥611.30m |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: 000504's short term assets (CN¥497.8M) exceed its short term liabilities (CN¥294.4M).
Long Term Liabilities: 000504's short term assets (CN¥497.8M) exceed its long term liabilities (CN¥15.1M).
Debt to Equity History and Analysis
Debt Level: 000504 has more cash than its total debt.
Reducing Debt: 000504's debt to equity ratio has reduced from 157.5% to 9.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 000504 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 000504 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 30.2% per year.